Auf dieser Seite
IMVT Immunovant, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$33,62
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$15,9552-Wochen-Tief
$45,4252-Wochen-Hoch
Marktkapitalisierung (MRQ)
$6.93B
P/E
-12.1
EPS
$-2.77
Ihre Abzeichen
52W-Spanne
$16–$45
Analystenbewertung
STRONG BUY
Kursziel
$49
P/E
-12.1
ROE
-73.7%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
IMVT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$33.62
Marktkapitalisierung (MRQ)
$6.93B
P/E
-12.1
EPS
$-2.77
ROE
-73.7%
52W-Spanne
$16–$45
IMVT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
EPS$-2.772021-03-31 → 2026-03-31
Freier Cashflow$-407M2020-03-31 → 2026-03-31
Nettogewinnmarge·2023-03-31 → 2024-03-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | IMVT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -12.15-Jahres-Durchschnitt ≈-9.1 | ≈-9.1 | · | · | |
| P/S | 351.45-Jahres-Durchschnitt ≈216.0 | ≈216.0 | 102.4 | Überbewertet | |
| K/B (MRQ) | 9.45-Jahres-Durchschnitt ≈4.9 | ≈4.9 | 9.0 | Teurer | |
| Price / FCF (Kurs / FCF) | -16.85-Jahres-Durchschnitt ≈-11.8 | ≈-11.8 | · | · | |
| Price / Cash Flow (Kurs / Cashflow) | -16.85-Jahres-Durchschnitt ≈-11.8 | ≈-11.8 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 8.05-Jahres-Durchschnitt ≈4.9 | ≈4.9 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | IMVT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | -58.3%5-Jahres-Durchschnitt ≈-48.7% | ≈-48.7% | -22.4% | Schwach | |
| ROE | -73.7%5-Jahres-Durchschnitt ≈-55.6% | ≈-55.6% | -47.3% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | IMVT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 7.35-Jahres-Durchschnitt ≈11.0 | ≈11.0 | 7.9 | Geringe Liquidität | |
| Quick Ratio | 8.65-Jahres-Durchschnitt ≈10.5 | ≈10.5 | 6.5 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | IMVT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 229.2% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Beat Rate
25.0%
Durchschn. Überraschung
-7.0%
Nächster Bericht
Nov 09, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 31. März 2027 | Aug 12, 2026 | $-0.75 | $-0.63 | -19.5% |
| 31. Dezember 2026 | Mai 20, 2026 | $-0.73 | $-0.61 | -19.1% |
| 30. Juni 2026 | $-0.75 | $-0.63 | -19.5% | |
| 31. März 2026 | $-0.73 | $-0.61 | -19.1% | |
| 31. Dezember 2025 | $-0.61 | $-0.73 | 16.3% | |
| 30. September 2025 | $-0.73 | $-0.73 | 0.21% | |
| 30. Juni 2025 | $-0.71 | $-0.66 | -8.0% | |
| 31. März 2025 | $-0.64 | $-0.73 | 12.4% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | · | · | · | · | $102M | $69M | $48M | $26M | |
| SG&A Expense | $76M | $77M | $57M | $48M | $54M | $40M | $18M | $3M | |
| Operating Expenses | $533M | $438M | $283M | $218M | $156M | $108M | $66M | $28M | |
| Interest Expense | · | · | · | · | · | $0 | $625.0K | · | |
| Other Non-op | $2M | $471.0K | $-1M | $-253.0K | $-781.0K | $328.0K | $412.0K | $-155.0K | |
| Pretax Income | $-505M | $-413M | $-259M | $-211M | $-157M | $-108M | $-66M | $-29M | |
| Income Tax | $215.0K | $891.0K | $567.0K | $9.0K | $-84.0K | $-358.0K | $97.0K | $19.0K | |
| Net Income | $-506M | $-414M | $-259M | $-211M | $-157M | $-107M | $-66M | $-29M | |
| EPS (Basic) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | · | · | |
| EPS (Diluted) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | · | · | |
| Shares (Basic) | 182,421,233 | 151,573,553 | 138,100,577 | 123,075,329 | 109,679,256 | 87,756,513 | · | · | |
| Shares (Diluted) | 182,421,233 | 151,573,553 | 138,100,577 | 123,075,329 | 109,679,256 | 87,756,513 | · | · |
Bilanz
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $902M | $714M | $635M | $377M | $494M | $400M | $101M | $7M | |
| Receivables | $1M | $2M | $5M | $700.0K | $12M | $596.0K | · | · | |
| Prepaid Expense | $46M | $51M | $25M | $27M | $6M | $8M | $5M | $3M | |
| Current Assets | $949M | $768M | $666M | $404M | $513M | $409M | $109M | $13M | |
| PP&E (Net) | $443.0K | $844.0K | $462.0K | $333.0K | $330.0K | $201.0K | $65.0K | $54.0K | |
| Other Non-current Assets | $8M | $8M | $0 | · | · | · | · | · | |
| Total Assets | $957M | $776M | $666M | $406M | $516M | $412M | $109M | $14M | |
| Accounts Payable | $8M | $18M | $7M | $1M | $19M | $2M | $1M | $206.0K | |
| Accrued Liabilities | $97M | $51M | $41M | $40M | $25M | $15M | $11M | $6M | |
| Current Liabilities | $104M | $69M | $49M | $43M | $45M | $19M | $15M | · | |
| Capital Leases | · | · | $0 | $47.0K | $1M | $2M | $0 | · | |
| Total Liabilities | $104M | $69M | $49M | $43M | $46M | $21M | $15M | $6M | |
| Common Stock | $20.0K | $16.0K | $14.0K | $13.0K | $12.0K | $10.0K | $5.0K | $4.0K | |
| Paid-in Capital | $2.60B | $1.95B | $1.44B | $928M | $825M | $590M | $185M | $32M | |
| Retained Earnings | $-1.75B | $-1.24B | $-826M | $-566M | $-355M | $-199M | $-91M | $-25M | |
| AOCI | $730.0K | $1M | $2M | $852.0K | $404.0K | $-298.0K | $-16.0K | $346.0K | |
| Stockholders' Equity | $853M | $707M | $618M | $362M | $470M | $391M | $94M | $7M | |
| Liabilities + Equity | $957M | $776M | $666M | $406M | $516M | $412M | $109M | $14M | |
| Shares Outstanding | 203,940,353 | 170,111,593 | 145,582,999 | 130,329,863 | 116,482,899 | 97,971,243 | 54,655,376 | 38,590,381 |
Cashflow
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $56M | $49M | $41M | $32M | $34M | $19M | $7M | $1M | |
| Deferred Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating Cash Flow | $-407M | $-376M | $-214M | $-188M | $-106M | $-83M | $-53M | $-29M | |
| CapEx | $8.0K | $759.0K | $360.0K | $197.0K | $254.0K | $210.0K | $31.0K | $52.0K | |
| Investing Cash Flow | $-8.0K | $-759.0K | $-360.0K | $-197.0K | $-254.0K | $-210.0K | $-31.0K | $-52.0K | |
| Stock Issued | $544M | $450M | $473M | · | · | · | · | $15M | |
| Net Stock Activity | $544M | · | · | · | · | · | · | · | |
| Financing Cash Flow | $596M | $454M | $472M | $71M | $200M | $383M | $147M | $36M | |
| Net Change in Cash | $188M | $79M | $259M | $-117M | $94M | $300M | $94M | $7M | |
| Taxes Paid | $2M | · | $509.0K | $0 | · | · | · | · | |
| Free Cash Flow | $-407M | $-377M | $-215M | $-188M | $-106M | $-84M | $-53M | · | |
| Levered FCF | · | · | · | · | · | $-84M | $-54M | · |
Rentabilität
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Net Margin | · | · | -1039.5% | -2783.8% | · | · | · | · | |
| Pretax Margin | · | · | -1037.2% | -2783.7% | · | · | · | · | |
| ROA | -58.3% | -57.4% | -48.4% | -45.8% | -33.8% | -41.2% | -107.8% | · | |
| ROE | -73.7% | -78.1% | -40.0% | -54.3% | -32.1% | -26.7% | -64.5% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.1 | 11.2 | 13.7 | 9.3 | 11.5 | 21.8 | · | · | |
| Quick Ratio | 8.6 | 10.4 | 13.2 | 8.7 | 11.4 | 21.3 | · | · |
Effizienz
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | · | · | · | · | |
| Receivables Turnover | · | · | 8.3 | 1.2 | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.18 | $4.16 | $4.24 | $2.78 | $4.03 | $4.00 | $1.72 | · | |
| Revenue / Share | · | · | $0.18 | $0.06 | · | · | · | · | |
| Cash Flow / Share | $-2.23 | $-2.48 | $-1.55 | $-1.53 | $-0.97 | · | · | · | |
| Cash / Share | $4.42 | $4.20 | $4.36 | $2.89 | $4.24 | $4.08 | $1.84 | · | |
| EPS (TTM) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | · | · |
Wachstumsraten
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | 229.2% | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $20M | $20M | $25M | $8M | $0 | · | · | · | |
| Net Income TTM | $-506M | $-414M | $-259M | $-211M | $-157M | $-107M | $-66M | · | |
| Market Cap | $5.07B | $2.91B | $4.70B | $2.02B | $642M | $1.57B | $851M | · | |
| P/E | -9.0 | -6.3 | -17.2 | -9.1 | -3.9 | -13.1 | · | · | |
| P/S | 259.6 | 149.0 | 188.5 | 266.7 | · | · | · | · | |
| P/B | 5.9 | 4.1 | 7.6 | 5.6 | 1.4 | 4.0 | 9.0 | · | |
| P / Tangible Book | 5.9 | 4.1 | 7.6 | 5.6 | 1.4 | 4.0 | · | · | |
| P / Cash Flow | -12.4 | -7.7 | -22.0 | -10.7 | -6.0 | -18.9 | -15.9 | · | |
| P / FCF | -12.4 | -7.7 | -21.9 | -10.7 | -6.0 | -18.8 | -15.9 | · | |
| Earnings Yield | -11.2% | -16.0% | -5.8% | -11.0% | -25.9% | -7.6% | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $38M | $28M | |
| SG&A Expense | $18M | $17M | $15M | $18M | $26M | $20M | $20M | $18M | $19M | $15M | $13M | $14M | $15M | $12M | $12M | $12M | |
| Operating Expenses | $160M | $160M | $114M | $132M | $127M | $114M | $114M | $116M | $94M | $81M | $62M | $62M | $78M | $64M | $50M | $40M | |
| Other Non-op | $4.0K | $798.0K | $-54.0K | $250.0K | $1M | $1M | $-1M | $629.0K | $28.0K | $-3M | $1M | $20.0K | $464.0K | $-2M | $793.0K | $354.0K | |
| Pretax Income | $-153M | $-151M | $-109M | $-126M | $-120M | $-106M | $-111M | $-109M | $-87M | $-75M | $-52M | $-58M | $-74M | $-63M | $-48M | $-40M | |
| Income Tax | $0 | $-3M | $2M | $594.0K | $913.0K | $584.0K | $152.0K | $78.0K | $77.0K | $232.0K | $-108.0K | $454.0K | $-11.0K | $387.0K | $261.0K | $352.0K | |
| Net Income | $-153M | $-148M | $-111M | $-127M | $-121M | $-106M | $-111M | $-109M | $-87M | $-75M | $-51M | $-59M | $-74M | $-63M | $-48M | $-40M | |
| EPS (Basic) | $-0.75 | $-0.72 | $-0.61 | $-0.73 | $-0.71 | $-0.63 | $-0.76 | $-0.74 | $-0.60 | $-0.50 | $-0.36 | $-0.45 | $-0.57 | $-0.49 | $-0.41 | $-0.35 | |
| EPS (Diluted) | $-0.75 | $-0.72 | $-0.61 | $-0.73 | $-0.71 | $-0.63 | $-0.76 | $-0.74 | $-0.60 | $-0.50 | $-0.36 | $-0.45 | $-0.57 | $-0.49 | $-0.41 | $-0.35 | |
| Shares (Basic) | 205,545,373 | · | 181,513,386 | 173,643,829 | 170,872,994 | · | 146,922,338 | 146,468,991 | 146,085,729 | · | 144,523,034 | 131,155,642 | 130,503,264 | 128,574,190 | 116,572,820 | 116,557,508 | |
| Shares (Diluted) | 205,545,373 | · | 181,513,386 | 173,643,829 | 170,872,994 | · | 146,922,338 | 146,468,991 | 146,085,729 | · | 144,523,034 | 131,155,642 | 130,503,264 | 128,574,190 | 116,572,820 | 116,557,508 |
Bilanz
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $798M | $902M | $995M | $522M | $599M | $714M | $375M | $473M | $560M | $635M | $691M | $270M | $330M | $433M | $406M | $427M | |
| Receivables | $697.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $5M | $1M | $1M | $823.0K | $704.0K | $4M | $13M | |
| Prepaid Expense | $53M | $43M | $47M | $50M | $51M | $51M | $36M | $33M | $27M | $25M | $19M | $20M | $19M | $21M | $17M | $16M | |
| Current Assets | $851M | $949M | $1.04B | $574M | $652M | $768M | $413M | $507M | $589M | $666M | $711M | $291M | $350M | $454M | $426M | $456M | |
| PP&E (Net) | $351.0K | $443.0K | $531.0K | $632.0K | $737.0K | $844.0K | $752.0K | $671.0K | $565.0K | $462.0K | $376.0K | $304.0K | $325.0K | $362.0K | $312.0K | $328.0K | |
| Other Non-current Assets | $961.0K | $8M | $9M | $9M | $9M | $8M | $8M | $8M | · | $0 | · | · | · | · | · | · | |
| Total Assets | $852M | $957M | $1.05B | $583M | $661M | $776M | $421M | $516M | $590M | $666M | $711M | $292M | $351M | $456M | $428M | $459M | |
| Accounts Payable | $10M | $8M | $9M | $7M | $8M | $18M | $20M | $21M | $11M | $7M | $4M | $8M | $26M | $14M | $7M | $1M | |
| Accrued Liabilities | · | $97M | · | · | · | $51M | $48M | $46M | $34M | $41M | $28M | $32M | $24M | $26M | $23M | $19M | |
| Current Liabilities | $117M | $104M | $66M | $63M | $53M | $69M | $68M | $67M | $45M | $49M | $32M | $40M | $51M | $41M | $32M | $21M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $306.0K | $614.0K | $919.0K | |
| Total Liabilities | $117M | $104M | $66M | $63M | $53M | $69M | $68M | $67M | $45M | $49M | $32M | $40M | $51M | $42M | $32M | $22M | |
| Common Stock | $20.0K | $20.0K | $20.0K | $17.0K | $16.0K | $16.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $13.0K | $13.0K | $13.0K | $12.0K | $12.0K | |
| Paid-in Capital | $2.63B | $2.60B | $2.58B | $2.00B | $1.97B | $1.95B | $1.48B | $1.47B | $1.46B | $1.44B | $1.43B | $950M | $940M | $920M | $841M | $833M | |
| Retained Earnings | $-1.90B | $-1.75B | $-1.60B | $-1.49B | $-1.36B | $-1.24B | $-1.13B | $-1.02B | $-913M | $-826M | $-750M | $-699M | $-640M | $-507M | $-444M | $-396M | |
| AOCI | $725.0K | $730.0K | $1M | $1M | $2M | $1M | $2M | $2M | $2M | $2M | $-600.0K | $513.0K | $582.0K | $1M | $-1M | $-263.0K | |
| Stockholders' Equity | $735M | $853M | $986M | $520M | $609M | $707M | $353M | $449M | $545M | $618M | $679M | $252M | $300M | $415M | $396M | $436M | |
| Liabilities + Equity | $852M | $957M | $1.05B | $583M | $661M | $776M | $421M | $516M | $590M | $666M | $711M | $292M | $351M | $456M | $428M | $459M | |
| Shares Outstanding | 206,264,878 | 203,940,353 | 203,316,885 | 174,532,710 | 171,069,176 | 170,111,593 | 147,203,565 | 146,565,049 | 146,195,673 | 145,582,999 | 145,094,052 | 131,442,024 | 130,565,429 | 129,260,254 | 116,614,088 | 116,524,158 |
Cashflow
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $14M | $11M | $13M | $13M | $19M | $12M | $12M | $13M | $13M | $10M | $10M | $11M | $11M | $9M | $8M | $8M | |
| Operating Cash Flow | $-124M | $-95M | $-92M | $-103M | $-117M | $-111M | $-100M | $-89M | $-76M | $-60M | $-47M | $-60M | $-47M | $-46M | $-20M | $-66M | |
| CapEx | · | $8.0K | $0 | $0 | $0 | $201.0K | $180.0K | $196.0K | $182.0K | $150.0K | $131.0K | $34.0K | $45.0K | $98.0K | $31.0K | $42.0K | |
| Investing Cash Flow | · | $-8.0K | $0 | $0 | $0 | $-201.0K | $-180.0K | $-196.0K | $-182.0K | $-150.0K | $-131.0K | $-34.0K | $-45.0K | $-98.0K | $-31.0K | $-42.0K | |
| Stock Issued | · | $0 | · | · | · | $450M | · | · | · | · | · | · | · | $70M | · | · | |
| Financing Cash Flow | $20M | $4M | $565M | $25M | $3M | $451M | $2M | $730.0K | $686.0K | $2M | $470M | $148.0K | $890.0K | $71M | $0 | $21.0K | |
| Net Change in Cash | $-104M | $-92M | $473M | $-77M | $-115M | $339M | $-98M | $-87M | $-75M | $-56M | $421M | $-60M | $-47M | $27M | $-21M | $-67M | |
| Free Cash Flow | · | · | · | · | $-117M | · | · | · | $-76M | · | · | · | $-47M | · | · | $-66M |
Rentabilität
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | · | · | · | · | · | · | · | · | · | · | -575.6% | -1642.3% | -1818.9% | -2147.7% | -4153.2% | · | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | -576.8% | -1629.6% | -1819.1% | -2134.5% | -4130.6% | · | |
| ROA | -20.2% | · | -15.0% | -23.0% | -19.3% | · | -19.6% | -27.0% | -18.5% | · | -8.8% | -16.3% | -18.3% | -12.7% | -9.6% | -9.5% | |
| ROE | -22.8% | · | -16.5% | -26.1% | -20.9% | · | -21.5% | -31.1% | -20.6% | · | -9.4% | -18.1% | -20.1% | -13.8% | -10.3% | -10.1% |
Liquidität & Solvenz
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.3 | · | 15.7 | 9.1 | 12.3 | · | 6.0 | 7.6 | 13.1 | · | 22.1 | 7.2 | 6.8 | 11.0 | 13.4 | 21.5 | |
| Quick Ratio | 6.8 | · | 15.0 | 8.3 | 11.4 | · | 5.5 | 7.1 | 12.5 | · | 21.6 | 6.7 | 6.4 | 10.5 | 12.9 | 20.7 |
Effizienz
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | · | · | · | · | · | · | · | · | · | · | 10.3 | 1.4 | 0.6 | 8.4 | 0.6 | · |
Pro Aktie
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.57 | · | $4.85 | $2.98 | $3.56 | · | $2.40 | $3.06 | $3.73 | · | $4.68 | $1.92 | $2.30 | $3.21 | $3.39 | $3.75 | |
| Revenue / Share | · | · | · | · | · | · | · | · | · | · | $0.06 | $0.03 | $0.03 | $0.02 | $0.01 | · | |
| Cash Flow / Share | $-0.61 | · | · | · | $-0.69 | · | · | · | $-0.52 | · | · | · | $-0.36 | · | · | $-0.56 | |
| Cash / Share | $3.87 | · | $4.89 | $2.99 | $3.50 | · | $2.55 | $3.23 | $3.83 | · | $4.76 | $2.05 | $2.53 | $3.35 | $3.48 | $3.67 | |
| EPS (TTM) | $-2.81 | · | $-2.68 | $-2.83 | $-2.84 | · | $-2.60 | $-2.20 | $-1.91 | · | $-1.84 | $-1.97 | $-1.93 | $-1.66 | $-1.53 | $-1.47 |
Bewertung (TTM)
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | $1M | $0 | |
| Net Income TTM | $-538M | · | $-464M | $-465M | $-447M | · | $-383M | $-323M | $-273M | · | $-243M | $-255M | $-245M | $-199M | $-177M | $-167M | |
| Market Cap | $7.95B | · | $5.17B | $2.81B | $2.74B | · | $3.65B | $4.18B | $3.86B | · | $6.11B | $5.05B | $2.48B | $2.29B | $651M | $454M | |
| P/E | -13.7 | · | -9.5 | -5.7 | -5.6 | · | -9.5 | -13.0 | -13.8 | · | -22.9 | -19.5 | -9.8 | -10.7 | -3.6 | -2.7 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 559.9 | 563.9 | · | |
| P/B | 10.8 | · | 5.2 | 5.4 | 4.5 | · | 10.3 | 9.3 | 7.1 | · | 9.0 | 20.0 | 8.3 | 5.5 | 1.6 | 1.0 | |
| P / Tangible Book | 10.8 | · | 5.2 | 5.4 | 4.5 | · | 10.3 | 9.3 | 7.1 | · | 9.0 | 20.0 | 8.3 | 5.5 | 1.6 | 1.0 | |
| P / Cash Flow | -63.9 | · | · | · | -23.3 | · | · | · | -50.7 | · | · | · | -52.3 | · | · | -6.9 | |
| Earnings Yield | -7.3% | · | -10.5% | -17.6% | -17.8% | · | -10.5% | -7.7% | -7.2% | · | -4.4% | -5.1% | -10.2% | -9.3% | -27.4% | -37.7% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Nettoergebnis | $-506M | $-414M | $-259M | $-211M | $-157M |
| Verwässerte EPS | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 |
| Kennzahl | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 9.1 | 11.2 | 13.7 | 9.3 | 11.5 |
| Quick Ratio | 8.6 | 10.4 | 13.2 | 8.7 | 11.4 |
| Kennzahl | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-407M | $-377M | $-215M | $-188M | $-106M |
Institutionelle Eigentümer (13F) 246 Einreicher · $4.4B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
246
Gehaltener Wert
$4.4B
Neue Positionen
41
Geschlossene Positionen
21
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 41 (-8 vs. Vorquartal) | 21 (-2 vs. Vorquartal) | 75 (-19 vs. Vorquartal) | 81 (+37 vs. Vorquartal) | +645K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $623.664.634 | 16.186.469 | 14,33% | Aktien |
| Deep Track Capital, LP | $359.914.548 | 9.341.151 | 8,27% | Aktien |
| BlackRock, Inc. | $276.679.973 | 7.180.897 | 6,36% | Aktien |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $223.666.650 | 5.805.000 | 5,14% | Aktien |
| BAKER BROS. ADVISORS LP | $209.419.027 | 5.435.220 | 4,81% | Aktien |
| VANGUARD GROUP INC | $197.750.162 | 7.779.314 | 4,54% | Aktien |
| STATE STREET CORP | $177.893.203 | 4.617.005 | 4,09% | Aktien |
| MORGAN STANLEY | $174.727.164 | 4.534.833 | 4,01% | Aktien |
| TCG Crossover Management, LLC | $171.766.278 | 4.457.988 | 3,95% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $150.671.912 | 3.910.509 | 3,46% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $140.198.379 | 3.638.681 | 3,22% | Aktien |
| JENNISON ASSOCIATES LLC | $127.543.468 | 3.310.238 | 2,93% | Aktien |
| RTW INVESTMENTS, LP | $122.442.522 | 3.177.849 | 2,81% | Aktien |
| Two Seas Capital LP | $121.311.898 | 3.148.505 | 2,79% | Aktien |
| ADAR1 Capital Management, LLC | $89.802.487 | 2.330.716 | 2,06% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $86.115.373 | 2.234.602 | 1,98% | Aktien |
| Woodline Partners LP | $76.130.233 | 1.975.869 | 1,75% | Aktien |
| GOLDMAN SACHS GROUP INC | $67.473.081 | 1.751.183 | 1,55% | Aktien |
| ARMISTICE CAPITAL, LLC | $66.888.080 | 1.736.000 | 1,54% | Aktien |
| Alpine Global Management, LLC | $52.978.748 | 1.375.000 | 1,22% | Aktien |
| PERCEPTIVE ADVISORS LLC | $52.299.967 | 1.357.383 | 1,20% | Aktien |
| D. E. Shaw & Co., Inc. | $47.802.399 | 1.240.654 | 1,10% | Aktien |
| ARMISTICE CAPITAL, LLC | $46.236.000 | 1.200.000 | 1,06% | Kaufoption |
| BANK OF AMERICA CORP /DE/ | $45.521.345 | 1.181.452 | 1,05% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $39.397.426 | 1.022.513 | 0,90% | Aktien |
| Aberdeen Group plc | $33.021.366 | 857.030 | 0,76% | Aktien |
| NORTHERN TRUST CORP | $30.592.975 | 794.004 | 0,70% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $28.003.604 | 726.800 | 0,64% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $26.223.210 | 680.592 | 0,60% | Aktien |
| Logos Global Management LP | $25.622.450 | 665.000 | 0,59% | Aktien |
| SILVERARC CAPITAL MANAGEMENT, LLC | $23.853.769 | 619.096 | 0,55% | Aktien |
| Nuveen, LLC | $23.196.833 | 602.046 | 0,53% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $21.740.398 | 564.246 | 0,50% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $18.262.604 | 473.984 | 0,42% | Aktien |
| UBS Group AG | $18.190.861 | 472.122 | 0,42% | Aktien |
| Pictet Asset Management Holding SA | $17.814.692 | 462.359 | 0,41% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $12.663.963 | 328.678 | 0,29% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $12.332.336 | 320.071 | 0,28% | Aktien |
| JANE STREET GROUP, LLC | $11.959.712 | 310.400 | 0,27% | Kaufoption |
| Bank of New York Mellon Corp | $11.396.826 | 295.791 | 0,26% | Aktien |
| HighVista Strategies LLC | $10.706.447 | 277.873 | 0,25% | Aktien |
| STEMPOINT CAPITAL LP | $10.654.585 | 276.527 | 0,24% | Aktien |
| Tetragon Partners GP Ltd | $9.861.137 | 255.934 | 0,23% | Aktien |
| Soleus Capital Management, L.P. | $9.709.560 | 252.000 | 0,22% | Aktien |
| SUPERSTRING CAPITAL MANAGEMENT LP | $8.028.419 | 208.368 | 0,18% | Aktien |
| Granahan Investment Management, LLC | $7.951.513 | 206.372 | 0,18% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.050.990 | 183.000 | 0,16% | Kaufoption |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $6.288.096 | 163.200 | 0,14% | Verkaufsoption |
| CITADEL ADVISORS LLC | $6.169.539 | 160.123 | 0,14% | Aktien |
| ALGERT GLOBAL LLC | $6.158.635 | 159.840 | 0,14% | Aktien |
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. ×11 Einreichungen | 12. Dezember 2025 | 55,90% | Änderung | · | SEC |
| Roderick Wong, M.D. | 27. Dezember 2019 | · | Erste Einreichung | M&A / Verkauf | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 27 Insider · 17 Führungskräfte · 12 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Eric Venker | Chief Executive Officer | 1. Juli 2026 M | 254.280 | 0 | 3 | $-461.834 |
| Peter Salzmann | Chief Executive Officer | 16. April 2025 S | 1.178.191 | 0 | 0 | $0 |
| Roderick Wong, M.D. | Chief Executive Officer | 11. Dezember 2019 P | 902.498 | 0 | 0 | $0 |
| Tiago Girao | Chief Financial Officer | 23. Juli 2026 S | 240.798 | 0 | 3 | $-1.410.626 |
| Eva Renee Barnett | Chief Financial Officer | 16. April 2025 S | 396.774 | 0 | 0 | $0 |
| Connealy Pamela Yanchik | Chief Financial Officer | 19. März 2021 A | 46.200 | 0 | 0 | $0 |
| Melanie Gloria | Chief Operating Officer | 20. August 2026 S | 219.301 | 0 | 14 | $-1.600.150 |
| Christopher Van Tuyl | Chief Legal Officer | 23. September 2026 S | 176.545 | 0 | 10 | $-1.418.316 |
| Jay S Stout | Chief Technology Officer | 23. Juli 2026 S | 205.341 | 0 | 15 | $-2.271.089 |
| Michael Geffner | Chief Medical Officer | 22. Oktober 2025 S | 217.958 | 0 | 2 | $-70.117 |
| William L. Macias | Chief Medical Officer | 19. Februar 2025 S | 357.353 | 0 | 0 | $0 |
| Mark S. Levine | Chief Legal Officer | 20. November 2024 S | 319.228 | 0 | 0 | $0 |
| Julia G. Butchko | Chief Development Officer | 21. August 2024 S | 440.959 | 0 | 0 | $0 |
| Michael James Elliott | Chief Scientific Officer | 19. März 2021 A | 97.600 | 0 | 0 | $0 |
| Rita Jain | Chief Medical Officer | 19. März 2021 A | 129.365 | 0 | 0 | $0 |
| Bradford W Middlekauff | General Counsel | 15. Mai 2020 A | · | 0 | 0 | $0 |
| Robert K Zeldin | Chief Medical Officer | 18. Dezember 2019 A | · | 0 | 0 | $0 |
| Atul Pande | Direktor | 28. August 2026 M | 116.731 | 0 | 5 | $-424.650 |
| Andrew J. Fromkin | Direktor | 28. Mai 2026 M | 74.382 | 0 | 4 | $-7.955.300 |
| Robert Graham Susman | Direktor | 1. Mai 2026 S | 36.394 | 0 | 1 | $-67.979 |
| Douglas J. Hughes | Direktor | 7. April 2026 A | 134.653 | 0 | 2 | $-348.666 |
| Jake Bauer | Direktor | 7. April 2026 A | 38.896 | 0 | 0 | $0 |
| Frank Torti | Direktor | 7. April 2026 A | 1.009.228 | 0 | 0 | $0 |
| Roivant Sciences Ltd. | Direktor | 12. Dezember 2025 P | 113.317.007 | 1 | 0 | $349.999.986 |
| George V Migausky | Direktor | 1. April 2025 A | 137.251 | 0 | 0 | $0 |
| Myrtle S Potter | Direktor | 18. Dezember 2019 A | · | 0 | 0 | $0 |
| Health Sciences Holdings, LLC | 10%-Eigentümer | 18. Dezember 2019 J | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 33 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| GURU · Global X Funds | 1,59% | 25.151 NS | 31. Juli 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,77% | 9.245 NS | 31. Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,68% | 87.318 NS | 31. Juli 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,46% | 14.619 SH | 1. Oktober 2026 | Täglich |
| ESSC · Strategy Shares | 0,34% | 3.180 NS | 31. Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,23% | 618.035 SH | 11. September 2026 | Täglich |
| IWO · iShares Trust | 0,21% | 801.227 SH | 11. September 2026 | Täglich |
| PWS · Pacer Funds Trust | 0,19% | 1.193 NS | 31. Juli 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,19% | 91.474 SH | 19. August 2026 | Täglich |
| BKSE · BNY Mellon ETF Trust | 0,14% | 3.097 NS | 31. Juli 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,13% | 23.292 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,11% | 27.234 SH | 11. September 2026 | Täglich |
| IWM · iShares Trust | 0,11% | 2.184.173 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,11% | 40.851 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,10% | 490.917 SH | 19. August 2026 | Täglich |
| VBK · VANGUARD INDEX FUNDS | 0,09% | 1.086.290 SH | 19. August 2026 | Täglich |
| VFMO · VANGUARD WELLINGTON FUND | 0,05% | 28.526 SH | 19. August 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,04% | 1.883.385 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,04% | 199.146 SH | 19. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,04% | 31.197 SH | 1. Oktober 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 31.435 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 887.661 SH | 19. August 2026 | Täglich |
| WSML · iShares Trust | 0,02% | 4.355 SH | 11. September 2026 | Täglich |
| ESGV · VANGUARD WORLD FUND | 0,01% | 18.937 SH | 19. August 2026 | Täglich |
| ITOT · iShares Trust | 0,00% | 116.576 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 24.022 SH | 10. September 2026 | Täglich |
| TILT · FlexShares Trust | 0,00% | 2.430 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 2.600.899 SH | 19. August 2026 | Täglich |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 67.319 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.098 SH | 19. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,00% | 18 NS | 31. Juli 2026 | N-PORT |
| ISCB · iShares Trust | · | 3.864 SH | 11. September 2026 | Täglich |
| SMLF · iShares Trust | · | 16.335 SH | 11. September 2026 | Täglich |
IMVT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 23 Analysten
KAUF
Median-Ziel
$48.50
+44,3%
9 39,1%
Starker Kauf
9 39,1%
Kauf
5 21,7%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
16 Analysten · 2026-09-28Mittelwert-Ziel $48.88 +45,4%
Jetzt
Aktueller Preis $33.62
Tief$30.00
Mittelwert$48.88
Hoch$66.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| IMVT | $5.07B | -9.0 | 229.2% | · | -73.7% | · |
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | · |
| IONS | $12.92B | -33.2 | · | · | -68.1% | · |
| RYTM | $7.19B | -34.4 | 45.8% | -103.6% | -309.1% | · |
| IOVA | $1.12B | -2.5 | 60.6% | -148.4% | -56.0% | · |
| GRAL | $3.45B | -7.7 | 17.2% | -277.5% | -16.7% | · |
| CGON | $3.35B | -20.0 | 254.7% | -3985.0% | -22.6% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026